A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples